ArticleEuropean journal of nuclear medicine and molecular imaging2014
Role of [¹⁸F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer.
Article in European journal of nuclear medicine and molecular imaging, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 46 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 1 synthesis or guideline pooled it.
- CanBMJ open · 2021Pooled it
- Impact assessment of [18F]FDG PET/CT in predicting EGFR gene mutation status in patients with lung adenocarcinoma using recovery coefficient-based correction of semi-quantitative and volume-based PET metrics.Nuklearmedizin. Nuclear medicine · 2026Article
- An Integrated Clinical-Radiomics-Deep Learning Model Based onCancer medicine · 2025Article
- Construction of a radiogenomics predictive model for KRAS mutation status in patients with non-small cell lung cancer.Journal of thoracic disease · 2025Article
- Prediction of EGFR mutations in non-small cell lung cancer: a nomogram based onFrontiers in oncology · 2025Article
- ExplainableJournal of cancer research and clinical oncology · 2024Article
- The value of dynamic FDG PET/CT in the differential diagnosis of lung cancer and predicting EGFR mutations.BMC pulmonary medicine · 2024Article
- Subregion-specificAmerican journal of nuclear medicine and molecular imaging · 2024Article
- Ability ofCancers · 2023Article
- FDG PET texture indices as imaging biomarkers for epidermal growth factor receptor mutation status in lung adenocarcinoma.Scientific reports · 2023Article
- Association Analysis of Maximum Standardized Uptake Values Based onJournal of personalized medicine · 2023Article
- OptimalFrontiers in oncology · 2023Article
- Combination ofKorean journal of radiology · 2022Article
- The predictive value ofTranslational cancer research · 2022Article
- A Review of the Correlation Between Epidermal Growth Factor Receptor Mutation Status andFrontiers in oncology · 2022Review
- Recent and current advances in PET/CT imaging in the field of predicting epidermal growth factor receptor mutations in non-small cell lung cancer.Frontiers in oncology · 2022Review
- Evolutionary dynamics at the tumor edge reveal metabolic imaging biomarkers.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- KRAS mutation effects on the 2-[18F]FDG PET uptake of colorectal adenocarcinoma metastases in the liver.EJNMMI research · 2020Article
- Imaging Biomarkers of Tumour Proliferation and Invasion for Personalised Lung Cancer Therapy.Journal of personalized medicine · 2020Review
- Standardized uptake value (SUVCancer biology & therapy · 2020Article
Corrections and comments
- Erratum issuedZulueta, Javier [corrected to Zulueta, Javier J]
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe tumour molecular profile predicts the activity of epidermal growth factor receptor (EGFR) inhibitors in non-small-cell lung cancer (NSCLC). However, tissue availability and tumour heterogeneity limit its assessment. We evaluated whether [(18)F]FDG PET might help predict KRAS and EFGR mutation status in NSCLC.
methodsBetween January 2005 and October 2011, 340 NSCLC patients were tested for KRAS and EGFR mutation status. We identified patients with stage III and IV disease who had undergone [(18)F]FDG PET/CT scanning for initial staging. SUVpeak, SUVmax and SUVmean of the single hottest tumour lesions were calculated, and their association with KRAS and EGFR mutation status was assessed. A receiver operator characteristic (ROC) curve analysis and a multivariate analysis (including SUVmean, gender, age and AJCC stage) were performed to identify the potential value of [(18)F]FDG PET/CT for predicting KRAS mutation.
resultsFrom 102 patients staged using [(18)F]FDG PET/CT, 28 (27%) had KRAS mutation (KRAS+), 22 (22%) had EGFR mutation (EGFR+) and 52 (51%) had wild-type KRAS and EGFR profiles (WT). KRAS+ patients showed significantly higher [(18)F]FDG uptake than EGFR+ and WT patients (SUVmean 9.5, 5.7 and 6.6, respectively; p < 0.001). No significant differences were observed in [(18)F]FDG uptake between EGFR+ patients and WT patients. ROC curve analysis for KRAS mutation status discrimination yielded an area under the curve of 0.740 for SUVmean (p < 0.001). The multivariate analysis showed a sensitivity and specificity of 78.6% and 62.2%, respectively, and the AUC was 0.773.
conclusionNSCLC patients with tumours harbouring KRAS mutations showed significantly higher [(18)F]FDG uptake than WT patients, as assessed in terms of SUVpeak, SUVmax and SUVmean. A multivariate model based on age, gender, AJCC stage and SUVmean might be used as a predictive marker of KRAS mutation status in patients with stage III or IV NSCLC.
Indexed as
Identifiers
24990403What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.